Tag Archives: Rituxan®/MabThera®

Roche to present new data from Actemra®/RoActemra® and Rituxan®/MabThera® at the 2016 ACR/ARHP in Washington, D.C.

15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra/RoActemra data from GiACTA – the largest ever clinical trial in people with giant cell arteritis (GCA), a condition for which there has been no approved therapy … Read the full press release